Skip to content
Screener

Alumis Inc. ALMS Retained Earnings

Retained Earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.32B+25.8%
Amgen logo
AmgenAMGN
-$22.28B+13.4%
Immunome logo
ImmunomeIMNM
-$855.13M-42.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$220.98M-111%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$504.51M-24.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$691.48M-42.0%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, voting, $0.0001 par value; 492,815,092 voting shares authorized as of March 31, 2026 and December 31, 2025; 123,169,838 and 99,084,365 voting shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively129
Common stock, non-voting, $0.0001 par value; 7,184,908 non-voting shares authorized as of March 31, 2026 and December 31, 2025; 4,059,908 and 5,622,408 non-voting shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1
Additional paid-in capital1,562,4051,202,975
Accumulated other comprehensive income (loss)(467)188
Accumulated deficit(994,929)(901,876)
Total stockholders’ equity567,021301,297
Total liabilities and stockholders’ equity$671,588$411,940

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s retained earnings?
Alumis Inc. (ALMS) reported retained earnings of -$994.93M in Q1 2026.
How has Alumis Inc.'s retained earnings changed year-over-year?
Alumis Inc.'s retained earnings decreased by 31.3% year-over-year, from -$757.51M to -$994.93M.
What is the long-term trend for Alumis Inc.'s retained earnings?
Over 2 years (2023 to 2025), Alumis Inc.'s retained earnings has grown at a 57.3% compound annual growth rate (CAGR), from -$364.32M to -$901.88M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Alumis Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude